HJ Science and Technology, Inc.

Newomics, based in Berkeley, CA, offers a cutting-edge unified multiomics platform powered by their innovative multispray technology, providing a versatile dual nano-micro ion source for mass spectrometry applications in proteomics, metabolomics, single cell omics, and more. Their proprietary MEA chip and M3 emitter technology enhance LC-MS performance, offering increased sensitivity, robustness, and throughput for a wide range of applications including clinical diagnostics, biomarker discovery, drug development, and environmental monitoring. Generated from the website

Agenus, based in Berkeley, CA, is a biotechnology company focused on harnessing the power of the immune system to develop curative therapies for cancer patients. Their innovative approach includes developing next-generation antibodies like botensilimab to target cold tumors and enhance the efficacy and tolerability of immunotherapy. With a strong pipeline of immuno-oncology therapeutics and strategic partnerships with industry leaders, Agenus aims to expand the patient population benefiting from immunotherapy through combination approaches and cutting-edge research in antibody therapeutics, adoptive cell therapies, adjuvants, and vaccines.Generated from the website

Carmot Therapeutics Inc, based in Berkeley, CA, is a leading drug discovery and development company that focuses on improving clinical outcomes for individuals living with metabolic diseases such as obesity and diabetes. With a mission to make what matters possible, Carmot Therapeutics utilizes their innovative approach of chemotype evolution to expand the universe of therapeutic potential, offering new possibilities for patients. Recently acquired by Roche in early 2024, Carmot Therapeutics is now a member of the esteemed Roche Group, further strengthening their commitment to advancing healthcare. Driven by a passion for science and a singular focus on improving the lives of people with obesity and diabetes, Carmot Therapeutics is dedicated to making a difference. Their pipeline of innovative solutions, built on the principles of incretin receptor signaling bias and energy homeostasis, showcases their commitment to developing groundbreaking treatments. With a team of experienced leaders, advisors, investors, and partners, Carmot Therapeutics is at the forefront of scientific advancements in the field of metabolic diseases, offering exciting career opportunities for those ready to contribute to their mission.Generated from the website